Glucosamine, one of the most widely used over-the-counter supplements for joint pain, is associated with a higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease, according to neuroscientists at the University of Florida. Their findings were published in Nature Metabolism.
The conclusion rests on several strands of evidence. The team ran a large retrospective analysis of patient records, then looked for supporting biological signals using advanced imaging of human brain specimens and experiments in Alzheimer's disease mouse models. Taken together, the researchers frame the result as another piece in a broader mechanistic picture connecting metabolic dysregulation to neurodegeneration - the idea that how the brain handles fuel and nutrients shapes how fast damage accumulates.
The practical stakes are considerable. Roughly 7 million people in the United States are living with Alzheimer's, with millions more affected by related dementias such as Lewy body and frontotemporal dementia, and the researchers note that many of them regularly take a supplement that may be worsening their disease course. Mild cognitive impairment is precisely the stage where clinicians and families are watching most closely for signs of decline, which makes any modifiable influence on that transition worth scrutiny.
The researchers are clear that these results are preliminary. An association drawn from medical records cannot establish that glucosamine causes faster progression, and confirmation would require a human clinical trial designed to test the question directly. Anyone currently taking glucosamine, particularly people with a cognitive diagnosis, would be best served by raising it with their own physician rather than acting on a single study.